Skip to main content
. 2023 Sep 3;8(12):2529–2545. doi: 10.1016/j.ekir.2023.08.037

Figure 2.

Figure 2

Current obstacles to the widespread clinical adoption of belatacept, and potential avenues to surmount these obstacles and expand belatacept clinical use. AMR, antibody-mediated rejection; CNI, calcineurin inhibitor; DSA, donor-specific antibody.